INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ocata Therapeutics, Inc. of Commencement of an Investigation In Connection With the Fairness of the Sale of the Company to Astellas Pharma Inc.

NEW YORK--()--The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Ocata Therapeutics, Inc. (NASDAQGM: OCAT) stock prior to November 10, 2015.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Ocata Therapeutics, Inc. to Astellas Pharma Inc. for $8.50 per share in cash. To learn more about the investigation and your rights, go to:

http://zlk.9nl.com/ocata-therapeutics-ocat

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
Tel: 212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com

Release Summary

Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Ocata Therapeutics, Inc. to Astellas Pharma Inc.

Contacts

Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
Tel: 212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com